Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.
Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.
Vanda, Novartis end arbitration proceedings
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
